https://doi.org/10.55788/86eb89a5
Etrasimod is a selective sphingosine-1-phospate-receptor modulator that is currently evaluated for various immuno-inflammatory indications. Newly reported was data on ELEVATE UC 52 (NCT03945188) and ELEVATE UC 12 (NCT03996369), 2 phase 3 trials on UC that were conducted by Prof. William J Sandborn (University of California San Diego, CA, USA) and colleagues [1].
Participating adults in both studies suffered from moderate-to-severe UC defined by activity measures of a modified Mayo Score of 4‒9, plus a centrally read endoscopic subscore ≥2 beside a rectal bleeding subscore ≥1. In line with the previous history at baseline, the assessment was stratified according to the type of prior treatments and corticosteroid medication. The 2 trials randomised 354 (ELEVATE UC 12) and 433 (ELEVATE UC 52) patients 2:1 to the study drug groups with a regimen of 2 mg of etrasimod once daily or placebo. Between 61.8% and 62.9% of the patients in both studies had never received biologics or Janus kinase inhibitors before. While ELEVATE UC 12 involved a 12-week induction only setting, the design of ELEVATE UC 52 foresaw a 40-week period of therapy subsequent to induction over 12 weeks. Change to a currently still ongoing open-label extension trial (ELEVATE UC OLE; NCT03950232) was available for patients with treatment failure at week 12.
The presented results revealed that etrasimod met all its primary and secondary efficacy endpoints in both studies. The rate for the primary endpoint of clinical remission in ELEVATE UC 12 was 24.8% for etrasimod versus 15.2% for placebo (P=0.026). The respective outcomes in ELEVATE UC 52 were 27% versus 7.4% after 3 months and even higher after 1 year with 32.1% versus 6.7% (P˂0.001 for both comparisons). The secondary endpoints included: mucosal healing, endoscopic improvement, symptomatic remission, and sustained clinical remission. Steroid-free remission was achieved in >4-fold more patients on etrasimod than on placebo (32.1% vs 6.7%; P<0.001).
The researchers pointed out that in both studies, treatment-emergent adverse events (AE) and serious AEs were similarly reported between treatment groups. They also highlighted that there were no serious AEs of bradycardia or atrioventricular block. The most common AEs in ELEVATE UC 52 were headache, nausea, and SARS-CoV-2 infection.
- Sandborn WJ, et al. Etrasimod 2 mg once daily as treatment for moderately to severely active ulcerative colitis: results from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 Lecture 968a, Digestive Disease Week 2022, 21‒24 May, San Diego, CA, USA.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Colonoscopy in UC: less pain and reduced recurrence with CO2 insufflation Next Article
IL-23 inhibition beneficial in maintenance treatment of UC »
« Colonoscopy in UC: less pain and reduced recurrence with CO2 insufflation Next Article
IL-23 inhibition beneficial in maintenance treatment of UC »
Table of Contents: DDW 2022
Featured articles
Too much hygiene: CD in later life?
IBD
Antibiotic use elevates IBD risks in senior citizens
Too much hygiene: CD in later life?
Biologic treatment decreases dementia risk in senior IBD patients
CD: Induction treatment with upadacitinib successful in clinical and endoscopic ratings
IL-23 inhibition beneficial in maintenance treatment of UC
Positive outcomes for etrasimod in UC
Colonoscopy in UC: less pain and reduced recurrence with CO2 insufflation
Upper GI
Substantial increase of oesophageal cancer prevalence in the middle-aged
Cannabis users need more sedation medication for gastroscopy
Preterm delivery and NICU admission are associated with the development of eosinophilic oesophagitis
Dupilumab promising as treatment for eosinophilic oesophagitis
Other Highlighted Research
AI-assisted colonoscopy improves adenoma detection
Faecal microbiota transplantation: a safe procedure to treat recurrent Clostridium difficile infections
Oral microbes effective for prevention of recurrent Clostridium difficile infections
Octreotide therapy beats standard of care in GIADs
Improvement in hepatic steatosis but worse lipid profile after alcohol cessation
Normal BMI in NAFLD patients is associated with a higher risk of cardiovascular disease
COVID-19 increases the mortality rates of patients with ALD
Related Articles
September 22, 2020
Severe COVID-19 less common in patients with GI symptoms
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com